期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 66, 期 9, 页码 -出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.00687-22
关键词
nontuberculous mycobacteria; omadacycline; combination regimen
资金
- department of Pulmonary Immunology [423500/14000]
- University of Texas System STARS award [250439/39411]
- National Institute of Allergy and Infectious Diseases [1R21AI148096]
- NIAID [R01 AI137080, U01 AI150508]
This study found that omadacycline has efficacy against Mycobacterium kansasii pulmonary disease and could be used in combination with moxifloxacin and tedizolid to potentially shorten the currently recommended 12-month therapy duration.
The 12-month therapy duration for the treatment of Mycobacterium kansasii pulmonary disease calls for more efficacious drugs for better treatment outcomes and to shorten the therapy duration. We performed (i) omadacycline MIC with M. kansasii ATCC 12478 strain and 21 clinical isolates, (ii) dose-response study in the hollow fiber system model of M. kansasii (HFS-Mkn) with six human equivalent omadacycline daily doses to determine the optimal drug exposure for the maximal kill, and (iii) a second HFS-Mkn study to determine the efficacy of omadacycline (300 mg/day) plus moxifloxacin (600 mg/day) plus tedizolid (200 mg/day) combination regimen with standard regimen as comparator. GraphPad Prism was used for data analysis and graphing. MIC of the reference strain was 4 mg/L but ranged from 8 to 32 mg/L among the 21 clinical isolates. In the HFS-Mkn, the exposure required for 50% of the maximal effect (EC50) was an omadacycline area under the concentration-time curve to MIC (AUC(0-24)/MIC) ratio of 1.95. The optimal exposure was an AUC(0-24)/MIC of 3.05, which could be achieved with 300 mg/day clinical dose. The omadacycline-moxifloxacin-tedizolid combination sterilized the HFS-Mkn in 14 days with a linear-regression based kill rate of -0.309 +/- 0.044 log(10) CFU/mL/day compared to the kill rate of -0.084 +/- 0.036log(10) CFU/mL/day with the standard regimen or 3.7-times faster. Omadacycline has efficacy against M. kansasii and could be used at 300 mg/day in combination with moxifloxacin and tedizolid for the treatment of M. kansasii pulmonary diseases with the potential to shorten the currently recommended 12-month therapy duration.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据